Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Advancing Health in Africa

2.

Spouses of Cancer Patients May Be at Increased Risk of Suicide

3.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

4.

For treatment, the majority of cancer patients choose complementary therapies.

5.

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot